TICKERNOMICS Sign up
Last Update: 2023-12-23 06:00:42
Tarsus Pharmaceuticals Inc. ( TARS ) https://www.tarsusrx.com
20.10USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
TARS
38.53%
SPY
30.72%
-55.97%
TARS
SPY
112.82%
TARS
0.00%
SPY
201.04%
TARS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
583.36
593.70
0.26
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.53
19.68
2.73
-14.42
0.00
-5.45
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-2187.87
79.85
-367.54
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-89.90
-73.52
0.00
Other Earnings and Cash Flow Stats:
Tarsus Pharmaceuticals Inc. ( TARS ) Net Income TTM ($MM) is -96.62
Tarsus Pharmaceuticals Inc. ( TARS ) Operating Income TTM ($MM) is -103.85
Tarsus Pharmaceuticals Inc. ( TARS ) Owners' Earnings Annual ($MM) is 0.00
Tarsus Pharmaceuticals Inc. ( TARS ) Current Price to Owners' Earnings ratio is 0.00
Tarsus Pharmaceuticals Inc. ( TARS ) EBITDA TTM ($MM) is -98.09
Tarsus Pharmaceuticals Inc. ( TARS ) EBITDA Margin is -367.54%
Capital Allocation:
Tarsus Pharmaceuticals Inc. ( TARS ) has paid 0.00 dividends per share and bought back -3.960066 million shares in the past 12 months
Tarsus Pharmaceuticals Inc. ( TARS ) has increased its debt by 9.885 million USD in the last 12 months
Capital Structure:
Tarsus Pharmaceuticals Inc. ( TARS ) Interest-bearing Debt ($MM) as of last quarter is 30
Tarsus Pharmaceuticals Inc. ( TARS ) Annual Working Capital Investments ($MM) are 32
Tarsus Pharmaceuticals Inc. ( TARS ) Book Value ($MM) as of last quarter is 213
Tarsus Pharmaceuticals Inc. ( TARS ) Debt/Capital as of last quarter is 14%
Other Balance Sheet Stats:
Tarsus Pharmaceuticals Inc. ( TARS ) has 226 million in cash on hand as of last quarter
Tarsus Pharmaceuticals Inc. ( TARS ) has 23 million of liabilities due within 12 months, and long term debt 29 as of last quarter
Tarsus Pharmaceuticals Inc. ( TARS ) has 30 common shares outstanding as of last quarter
Tarsus Pharmaceuticals Inc. ( TARS ) has 0 million USD of preferred stock value
Academic Scores:
Tarsus Pharmaceuticals Inc. ( TARS ) Altman Z-Score is 5.11 as of last quarter
Tarsus Pharmaceuticals Inc. ( TARS ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Tarsus Pharmaceuticals Inc. ( TARS ) largest shareholder is Geode Capital Management, LLC owning 526260 shares at 10.58 ($MM) value
Dianne C Whitfield(an insider) Sold 8355 shares of Tarsus Pharmaceuticals Inc. ( TARS ) for the amount of $136270.05 on 2023-11-30
10.55% of Tarsus Pharmaceuticals Inc. ( TARS ) is held by insiders, and 81.09% is held by institutions
Tarsus Pharmaceuticals Inc. ( TARS ) went public on 2020-10-16
Other Tarsus Pharmaceuticals Inc. ( TARS ) financial metrics:
FCF:-88.76
Unlevered Free Cash Flow:30.51
EPS:-5.11
Operating Margin:-2187.87
Gross Profit Margin:79.85
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-73.29
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Tarsus Pharmaceuticals Inc. ( TARS ) :
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.